Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.58 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29458124 | 1.00 | CHRNB2 (0.58) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD | |
| SCHEMBL9099265 | 0.92 | CHRNB2 (0.51) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD | |
| SCHEMBL29769084 | 0.89 | MAPT (0.62) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD | |
| SCHEMBL3442514 | 0.89 | MAPT (0.62) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD | |
| SCHEMBL4548252 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA4MAPTALDH1A1CYP3A4 | |
| SCHEMBL5509909 | 0.84 | CHRNB2 (0.59) | CHRNB2CHRNA4ALDH1A1CYP3A4CYP19A1 | |
| SCHEMBL1663340 | 0.84 | CYP19A1 (0.59) | MAPTSMN1; SMN2HPGDRAB9ALMNA | |
| SCHEMBL5275797 | 0.83 | CHRNB2 (0.58) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD | |
| SCHEMBL1219905 | 0.83 | CHRNB2 (0.58) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD | |
| SCHEMBL7399032 | 0.83 | CHRNB2 (0.58) | CHRNB2CHRNA4MAPTSMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | LEUKOS BIOTECH, S.L. (ES) | 2026-02-03 | — | — | US | disclosed |
| EP-4445901-A2 | NEW POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | Leukos Biotech, S.L. (ES) | 2024-10-16 | — | — | EP | disclosed |
| EP-4225753-B1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2024-07-31 | — | — | EP | disclosed |
| US-20240166639-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH, S.L. (ES) | 2024-05-23 | — | — | US | disclosed |
| EP-4225753-A1 | POTENT AND SELCTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | Leukos Biotech, S.L. (ES) | 2023-08-16 | — | — | EP | disclosed |
| EP-0777650-B1 | BIPHENYLAMIDE DERIVATIVES AS 5HT 1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-03-07 | — | — | EP | disclosed |
| US-5889022-A | Indole, indoline and quinoline derivatives with 5HT1D (anti-depressive) activity | SMITHKLINE BEECHAM, P.L.C. (GB) | 1999-03-30 | — | — | US | disclosed |
| WO-1998050346-A2 | ACETAMIDE AND UREA DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1998-11-12 | — | — | WO | disclosed |
| US-5817833-A | Biphenylamide compounds as 5HT1D Antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-10-06 | — | — | US | disclosed |
| US-5801170-A | Heterocyclic biphenylylamides useful as 5HT1D antagonists | SMITHKLINE BEECHAM PLC (GB) | 1998-09-01 | — | — | US | disclosed |
| EP-0736023-B1 | INDOLE, INDOLINE AND QUINOLINE DERIVATIVES WITH 5HT 1D (ANTI-DEPRESSIVE) ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1998-07-08 | — | — | EP | disclosed |
| EP-0777650-A1 | BIPHENYLAMIDE DERIVATIVES AS 5HT 1D? ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-06-11 | — | — | EP | disclosed |
| EP-0736023-A1 | INDOLE, INDOLINE AND QUINOLINE DERIVATIVES WITH 5HT 1D? (ANTI-DEPRESSIVE) ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1996-10-09 | — | — | EP | disclosed |
| EP-0733048-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-09-25 | — | — | EP | disclosed |
| WO-1996006079-A1 | BIPHENYLAMIDE DERIVATIVES AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-29 | — | — | WO | disclosed |
| WO-1995017398-A1 | INDOLE, INDOLINE AND QUINOLINE DERIVATIVES WITH 5HT1D (ANTI-DEPRESSIVE) ACTIVITY | SMITHKLINE BEECHAM PLC (GB) | 1995-06-29 | — | — | WO | disclosed |
| WO-1995015954-A1 | HETEROCYCLIC BIPHENYLYLAMIDES USEFUL AS 5HT1D ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | CHRNB2 104/4885CHRNA4 113/4885MAPT 4778/4885 |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | HTR3B, HTR1A, HTR1B | CHRNB2 113/4885CHRNA4 95/4885MAPT 4759/4885 |
| US-20240166639-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR1B, HTR1A, HTR3B | CHRNB2 200/4885CHRNA4 291/4885MAPT 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.